AIMS To explore whether the combination of atorvastatins and resveratrol is superior to each individual drug alone regarding re-endothelialization after drug-eluting stents (DESs) implantation. MATERIALS AND METHODS Ninety-four rabbits were randomized into control, atorvastatin, resveratrol, and combined medication groups. Abdominal aorta injury was induced via ballooning, followed by DES implantation. Neointimal formation and re-endothelialization after stent implantation were assessed via optical coherence tomography and scanning electron microscopy. The effects of resveratrol and atorvastatin on bone marrow-derived mesenchymal derived stem cells (BMSCs) were assessed. KEY FINDINGS Compared with the findings in the resveratrol and atorvastatin groups, the neointimal area and mean neointimal thickness were greater in the combined medication group, which also exhibited improved re-endothelialization. Compared with the effects of monotherapy, combined treatment further protected BMSCs against rapamycin-induced apoptosis and improved cell migration. Combined medication significantly upregulated Akt, p-Akt, eNOS, p-eNOS, and CXCR4 expression in BMSCs compared with the effects of monotherapy, and these effects were abolished by the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002. SIGNIFICANCE The combination of atorvastatin and resveratrol has the potential of accelerating re-endothelialization after stent implantation, reducing the risk of thrombosis and improving the safety of DESs.

中文翻译：

---

白藜芦醇联合阿托伐他汀对药物洗脱支架植入后再内皮化的影响及其潜在机制。

目的探讨阿托伐他汀和白藜芦醇的组合在药物洗脱支架（DES）植入后的再内皮化方面是否优于单独的每种药物。材料与方法94只兔随机分为对照组，阿托伐他汀，白藜芦醇和联合用药组。腹主动脉损伤是通过气球引起的，然后植入DES。通过光学相干断层扫描和扫描电子显微镜评估支架植入后新内膜的形成和重新内皮化。评估白藜芦醇和阿托伐他汀对骨髓来源的间充质干细胞（BMSCs）的影响。主要发现与白藜芦醇和阿托伐他汀组的发现相比，在联合用药组中，新内膜面积和平均新内膜厚度均较大，这也显示出了改善的再内皮化。与单药治疗相比，联合治疗进一步保护了骨髓间充质干细胞免受雷帕霉素诱导的细胞凋亡并改善细胞迁移。与单一疗法相比，联合用药显着上调了BMSCs中Akt，p-Akt，eNOS，p-eNOS和CXCR4的表达，磷脂酰肌醇3-激酶（PI3K）抑制剂LY294002消除了这些作用。意义阿托伐他汀和白藜芦醇的组合具有在植入支架后加速内皮再血管化的潜力，降低了血栓形成的风险并提高了DESs的安全性。联合治疗可进一步保护BMSC免受雷帕霉素诱导的细胞凋亡并改善细胞迁移。与单一疗法相比，联合用药显着上调了BMSCs中Akt，p-Akt，eNOS，p-eNOS和CXCR4的表达，磷脂酰肌醇3-激酶（PI3K）抑制剂LY294002消除了这些作用。意义阿托伐他汀和白藜芦醇的组合具有在植入支架后加速内皮再血管化的潜力，可降低血栓形成的风险并提高DESs的安全性。联合治疗可进一步保护BMSC免受雷帕霉素诱导的细胞凋亡并改善细胞迁移。与单一疗法相比，联合用药显着上调了BMSCs中Akt，p-Akt，eNOS，p-eNOS和CXCR4的表达，磷脂酰肌醇3-激酶（PI3K）抑制剂LY294002消除了这些作用。意义阿托伐他汀和白藜芦醇的组合具有在植入支架后加速内皮再血管化的潜力，可降低血栓形成的风险并提高DESs的安全性。磷脂酰肌醇3-激酶（PI3K）抑制剂LY294002消除了这些作用。意义阿托伐他汀和白藜芦醇的组合具有在植入支架后加速内皮再血管化的潜力，可降低血栓形成的风险并提高DESs的安全性。磷脂酰肌醇3-激酶（PI3K）抑制剂LY294002消除了这些作用。意义阿托伐他汀和白藜芦醇的组合具有在植入支架后加速内皮再血管化的潜力，可降低血栓形成的风险并提高DESs的安全性。